Table 2.

Sweat chloride, FEV1, serum total bilirubin and ALT in subgroups of patients with CF at baseline and after 1 year treatment with ETI.

Patient subgruops	Sweat chloride (mEq/L)				FEV1				Total Bilirubin (mg/dL)				ALT
	Baseline	After 1 year of ETI	p	Delta (% of baseline)	Baseline	After 1 year of ETI	p	Delta (% of baseline)	Baseline	After 1 year of ETI	p	Delta (% of baseline)	Baseline	After 1 year of ETI	p	Delta (% of baseline)
F508del/class I-III mutation (n = 74)	94 (74–111)	48 (36–65)	< 0.001	54 (64–35)	56 (36–78)	71 (49–91)	< 0.001	27 (11–45)	0.49 (0.31–0.60)	0.70 (0.55–1.13)	< 0.001	50 (24–100)	22 (13–29)	26 (18–39)	< 0.001	29 (10–81)
F508del/class IV-VI mutation (n = 22)	57 (30–76)	32 (15–39)	0.028	59 (67–47)	63 (46–89)	82 (65–96)	< 0.001	13 (5–22)	0.60 (0.40–0.79)	0.89 (0.67–1.10)	0.008	42 (20–84)	13 (11–24)	23 (19–27)	0.021	85 (14–151)
p	< 0.001	0.021		0.582	0.089	0.197		0.019	0.072	0.227		0.635	0.159	0.613		0.065
Liver steatosis (n = 34)	95 (74–111)	41 (36–54)	< 0.001	57 (63–45)	60 (36–76)	79 (59–91)	< 0.001	26 (15–60)	0.50 (0.31–0.70)	0.70 (0.57–1.10)	< 0.001	50 (25–90)	24 (13–35)	30 (20–47)	0.005	32 (10–100)
No liver steatosis (n = 71)	74 (64–99)	48 (29–64)	< 0.001	52 (71–39)	56 (37–81)	72 (50–95)	< 0.001	17 (7–38)	0.50 (0.30–0.62)	0.76 (0.60–1.11)	< 0.001	57 (25–115)	18 (12–26)	23 (18–32)	< 0.001	33 (6–100)
p	0.049	0.688		0.548	0.619	0.772		0.047	0.701	0.853		0.602	0.255	0.068		0.709